Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
- PMID: 18338393
- DOI: 10.1002/humu.20676
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Abstract
Gaucher disease (GD) is an autosomal recessive disorder caused by the deficiency of glucocerebrosidase, a lysosomal enzyme that catalyses the hydrolysis of the glycolipid glucocerebroside to ceramide and glucose. Lysosomal storage of the substrate in cells of the reticuloendothelial system leads to multisystemic manifestations, including involvement of the liver, spleen, bone marrow, lungs, and nervous system. Patients with GD have highly variable presentations and symptoms that, in many cases, do not correlate well with specific genotypes. Almost 300 unique mutations have been reported in the glucocerebrosidase gene (GBA), with a distribution that spans the gene. These include 203 missense mutations, 18 nonsense mutations, 36 small insertions or deletions that lead to either frameshifts or in-frame alterations, 14 splice junction mutations, and 13 complex alleles carrying two or more mutations in cis. Recombination events with a highly homologous pseudogene downstream of the GBA locus also have been identified, resulting from gene conversion, fusion, or duplication. In this review we discuss the spectrum of GBA mutations and their distribution in the patient population, evolutionary conservation, clinical presentations, and how they may affect the structure and function of glucocerebrosidase.
Similar articles
-
Molecular analysis of Turkish Gaucher disease patients: identification of novel mutations in glucocerebrosidase (GBA) gene.Eur J Med Genet. 2008 Jul-Aug;51(4):315-21. doi: 10.1016/j.ejmg.2008.02.004. Epub 2008 Mar 4. Eur J Med Genet. 2008. PMID: 18586596
-
Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.Hum Mutat. 2000;15(2):181-8. doi: 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S. Hum Mutat. 2000. PMID: 10649495 Review.
-
An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.Proteins. 2008 Feb 15;70(3):882-91. doi: 10.1002/prot.21554. Proteins. 2008. PMID: 17803231
-
The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher disease.Hum Mutat. 2002 Apr;19(4):458-9. doi: 10.1002/humu.9024. Hum Mutat. 2002. PMID: 11933202
-
Gaucher disease: complexity in a "simple" disorder.Mol Genet Metab. 2004 Sep-Oct;83(1-2):6-15. doi: 10.1016/j.ymgme.2004.08.015. Mol Genet Metab. 2004. PMID: 15464415 Review.
Cited by
-
Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies.Front Pharmacol. 2024 Feb 13;15:1335058. doi: 10.3389/fphar.2024.1335058. eCollection 2024. Front Pharmacol. 2024. PMID: 38414738 Free PMC article. Review.
-
A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.Acta Neurol Belg. 2024 Feb 28. doi: 10.1007/s13760-024-02493-1. Online ahead of print. Acta Neurol Belg. 2024. PMID: 38413480 Review.
-
The Impact of 90 Parkinson's Disease-Risk Single Nucleotide Polymorphisms on Urinary Bis(monoacylglycerol)phosphate Levels in the Prodromal and PD Cohorts.Int J Mol Sci. 2024 Feb 14;25(4):2286. doi: 10.3390/ijms25042286. Int J Mol Sci. 2024. PMID: 38396963 Free PMC article.
-
Synaptic dysfunction and extracellular matrix dysregulation in dopaminergic neurons from sporadic and E326K-GBA1 Parkinson's disease patients.NPJ Parkinsons Dis. 2024 Feb 19;10(1):38. doi: 10.1038/s41531-024-00653-x. NPJ Parkinsons Dis. 2024. PMID: 38374278 Free PMC article.
-
Uncovering a New Family Cluster of Gaucher Disease: A Case Report.Cureus. 2024 Jan 3;16(1):e51604. doi: 10.7759/cureus.51604. eCollection 2024 Jan. Cureus. 2024. PMID: 38313996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
